CITIUS ONCOLOGY INC (CTOR) Stock Overview
NASDAQ:CTOR - US17331Y1091 - Common Stock
CTOR Key Statistics, Chart & Performance
The current stock price of CTOR is 2.17 USD. In the past month the price increased by 5.34%. In the past year, price increased by 22.6%.
CTOR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.87 | 371.68B | ||
| AMGN | AMGEN INC | 13.19 | 154.89B | ||
| GILD | GILEAD SCIENCES INC | 14.6 | 140.17B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.08 | 100.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 61.55B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.53B | ||
| ARGX | ARGENX SE - ADR | 76.83 | 43.59B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.16 | 36.38B | ||
| INSM | INSMED INC | N/A | 28.77B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.04B | ||
| NTRA | NATERA INC | N/A | 23.09B | ||
| BIIB | BIOGEN INC | 8.26 | 19.38B |
Related stock screener links
About CTOR
Company Profile
Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. The company is headquartered in New York City, New York. The company went IPO on 2022-10-14. The firm is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. The company is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.
Company Info
CITIUS ONCOLOGY INC
420 Lexington Ave, Suite 2446
New York City NEW YORK US
Employees: 0
Phone: 13476270058
CITIUS ONCOLOGY INC / CTOR FAQ
What is the stock price of CITIUS ONCOLOGY INC today?
The current stock price of CTOR is 2.17 USD. The price increased by 2.36% in the last trading session.
What is the ticker symbol for CITIUS ONCOLOGY INC stock?
The exchange symbol of CITIUS ONCOLOGY INC is CTOR and it is listed on the Nasdaq exchange.
On which exchange is CTOR stock listed?
CTOR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CITIUS ONCOLOGY INC stock?
6 analysts have analysed CTOR and the average price target is 3.06 USD. This implies a price increase of 41.01% is expected in the next year compared to the current price of 2.17. Check the CITIUS ONCOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CITIUS ONCOLOGY INC worth?
CITIUS ONCOLOGY INC (CTOR) has a market capitalization of 170.06M USD. This makes CTOR a Micro Cap stock.
How many employees does CITIUS ONCOLOGY INC have?
CITIUS ONCOLOGY INC (CTOR) currently has 0 employees.
What are the support and resistance levels for CITIUS ONCOLOGY INC (CTOR) stock?
CITIUS ONCOLOGY INC (CTOR) has a support level at 1.69. Check the full technical report for a detailed analysis of CTOR support and resistance levels.
Should I buy CITIUS ONCOLOGY INC (CTOR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CTOR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CTOR, evaluating the profitability, health, valuation and growth aspects
- CITIUS ONCOLOGY INC (CTOR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CITIUS ONCOLOGY INC (CTOR) Sales and EPS estimates to see what analysts future expectations are.
- CITIUS ONCOLOGY INC (CTOR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CITIUS ONCOLOGY INC (CTOR) Insider and Institutional Ownership to learn about the owners and their transactions.
- CITIUS ONCOLOGY INC (CTOR) Stock Chart to make your own analysis
- CITIUS ONCOLOGY INC (CTOR) Latest news and press-releases to stay up to date.
Does CITIUS ONCOLOGY INC (CTOR) stock pay dividends?
CTOR does not pay a dividend.
When does CITIUS ONCOLOGY INC (CTOR) report earnings?
CITIUS ONCOLOGY INC (CTOR) will report earnings on 2025-12-25.
What is the Price/Earnings (PE) ratio of CITIUS ONCOLOGY INC (CTOR)?
CITIUS ONCOLOGY INC (CTOR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.6).
What is the Short Interest ratio of CITIUS ONCOLOGY INC (CTOR) stock?
The outstanding short interest for CITIUS ONCOLOGY INC (CTOR) is 2.9% of its float. Check the ownership tab for more information on the CTOR short interest.
CTOR Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CTOR. When comparing the yearly performance of all stocks, CTOR is one of the better performing stocks in the market, outperforming 95.58% of all stocks.
CTOR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CTOR. CTOR may be in some trouble as it scores bad on both profitability and health.
CTOR Financial Highlights
Over the last trailing twelve months CTOR reported a non-GAAP Earnings per Share(EPS) of -0.6. The EPS decreased by -74.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -45.54% | ||
| ROE | -128.91% | ||
| Debt/Equity | 0.12 |
CTOR Forecast & Estimates
6 analysts have analysed CTOR and the average price target is 3.06 USD. This implies a price increase of 41.01% is expected in the next year compared to the current price of 2.17.